Related Experiment Video

Updated: Apr 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy

Yongli Ji1, Joanna Schwartz2, Alan Hartford3

  • 1University of Vermont Cancer Center, Burlington.

JAMA Oncology
|July 17, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Experiment Videos

Last Updated: Apr 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

565
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
565
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.

Research square·2026

Acute ST-Segment Elevation Myocardial Infarction Following Multimodality Cancer Therapy in a HER2-Positive Breast Cancer Patient: A Case Report.

Journal of cardiovascular development and disease·2026

Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3.

The oncologist·2026

Developing a job retention vocational rehabilitation intervention for people with long covid: a person-based approach.

BMJ open·2026

Early stroke specialist vocational rehabilitation for REturn To work After stroKE: a synopsis from the RETAKE RCT.

Health technology assessment (Winchester, England)·2026

How the Ketogenic Diet Shapes the Microbiome to Influence Cancer Immunotherapy Outcomes: An Exploration of Clinical Trials and Their Results.

Nutrition and cancer·2026

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

JAMA oncology·2026

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

JAMA oncology·2026

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review.

JAMA oncology·2026

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.

JAMA oncology·2026

Federal and Industry Sponsorship in US Cancer Clinical Trials.

JAMA oncology·2026

Trends in Meningioma Incidence, Treatment, and Imaging Surveillance.

JAMA oncology·2026

Targeted Delivery of Carvacrol via TPGS-Tf-Polydopamine Nanoconjugate Scaffold on TNBC Tumor Xenograft for Understanding In Vivo Tumor Dynamics and 3D Cancer Spheroid Model, Mimicking a Tumor Environment.

Molecular pharmaceutics·2026

Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells.

Molecular pharmaceutics·2026

Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation.

Molecular pharmaceutics·2026

Correlation Between the Extent of Lateral Neck Lymph Node Dissection and Postoperative Parathyroid Function in Papillary Thyroid Carcinoma.

Journal of investigative surgery : the official journal of the Academy of Surgical Research·2026

The role of particle therapy in the treatment of locally recurrent rectal cancer: a systematic review.

Radiology and oncology·2026

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience.

Radiology and oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us